Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22

Dana L. BakerDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA

Kun PengDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA

Melissa CheuDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA

Saloumeh Kadkhodayan FischerDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USACorrespondence[email protected]

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This letter was not funded.

Declaration of financial/other relationships

D.L.B., K.P., M.C., and S.K.F. have disclosed that they are employees of Genentech Inc., South San Francisco, CA, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22

Transparency

Declaration of funding

Declaration of financial/other relationships

Information for

Open access

Opportunities

Help and information

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22

Transparency

Declaration of funding

Declaration of financial/other relationships

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature